Patents by Inventor Timothy David Osslund

Timothy David Osslund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline antibody formulations
    Patent number: 11773184
    Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: October 3, 2023
    Inventors: Twinkle R. Christian, Christi L. Clogston, Timothy David Osslund
  • HIGH CONCENTRATION ANTIBODY FORMULATIONS
    Publication number: 20210275671
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Inventor: Timothy David Osslund
  • High concentration antibody formulations
    Patent number: 11040102
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventor: Timothy David Osslund
  • METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS
    Publication number: 20210047434
    Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.
    Type: Application
    Filed: September 3, 2020
    Publication date: February 18, 2021
    Inventors: Joyce Chi Yee Chan, John P. Gibbs, Clapton S. Dias, Scott Wasserman, Robert Andrew Donald Scott, Christi L. Clogston, Timothy David Osslund, Evan A. Stein
  • CRYSTALLINE ANTIBODY FORMULATIONS
    Publication number: 20200299410
    Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Application
    Filed: February 24, 2020
    Publication date: September 24, 2020
    Applicant: AMGEN INC.
    Inventors: Twinkle R. CHRISTIAN, Christi L. CLOGSTON, Timothy David OSSLUND
  • Crystalline antibody formulations
    Patent number: 10611850
    Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 7, 2020
    Assignee: Amgen Inc.
    Inventors: Twinkle R. Christian, Christi L. Clogston, Timothy David Osslund
  • High Concentration Antibody Formulations
    Publication number: 20190022230
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Application
    Filed: July 26, 2018
    Publication date: January 24, 2019
    Inventor: Timothy David Osslund
  • CRYSTALLINE ANTIBODY FORMULATIONS
    Publication number: 20170198058
    Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Application
    Filed: July 13, 2015
    Publication date: July 13, 2017
    Inventors: Twinkle R. CHRISTIAN, Christi L. CLOGSTON, Timothy David OSSLUND
  • High concentration antibody formulations
    Patent number: 9352043
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: May 31, 2016
    Assignee: AMGEN INC.
    Inventor: Timothy David Osslund
  • Sclerostin antibody crystals and formulations thereof
    Patent number: 9145457
    Abstract: Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: September 29, 2015
    Assignee: AMGEN INC.
    Inventors: Christi L. Clogston, Twinkle R. Christian, Timothy David Osslund, Elisabeth Freeman
  • HIGH CONCENTRATION ANTIBODY FORMULATIONS
    Publication number: 20130202620
    Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.
    Type: Application
    Filed: May 11, 2011
    Publication date: August 8, 2013
    Applicant: AMGEN INC.
    Inventor: Timothy David Osslund
  • METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS
    Publication number: 20130064825
    Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 14, 2013
    Applicant: Amgen Inc.
    Inventors: Joyce Chi Yee Chan, John P. Gibbs, Clapton S. Dias, Scott Wasserman, Robert Andrew Donald Scott, Christi L. Clogston, Timothy David Osslund
  • Keratinocyte growth factor-2 products
    Patent number: 6743422
    Abstract: The present invention concerns variants and chemical derivates of keratinocyte growth factor-2 (KGF-2) protein. Also disclosed are nucleic acid molecules encoding such variants, as well as methods for using such variants and chemical derivates to stimulate epithelial cell proliferation.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: June 1, 2004
    Assignee: Amgen, Inc.
    Inventors: Linda Owers Narhi, Timothy David Osslund
  • Uses of keratinocyte growth factor-2
    Publication number: 20040043924
    Abstract: The present invention concerns variants and chemical derivatives of keratinocyte growth factor-2 (KGF-2) protein. Also disclosed are nucleic acid molecules encoding such a variants, as well as methods for using such variants and chemical derivatives to stimulate epithelial cell proliferation.
    Type: Application
    Filed: September 19, 2003
    Publication date: March 4, 2004
    Inventors: Linda Owens Narhi, Timothy David Osslund
  • G-CSF analog compositions and methods
    Patent number: 6632426
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: October 14, 2003
    Assignee: Amgen Inc.
    Inventor: Timothy David Osslund
  • G-CSF analog compositions and methods
    Publication number: 20030171559
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
    Type: Application
    Filed: December 20, 2001
    Publication date: September 11, 2003
    Applicant: Amgen Inc.
    Inventor: Timothy David Osslund
  • G-CSF hybrid molecules and pharmaceutical compositions
    Patent number: 6261550
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) analogs and compositions containing such analogs which retain the three-dimensional structure of the internal core of the four alpha helical bundle of G-CSF. In another aspect, such G-CSF analogs can also be attached with biologically active proteins to form hybrid molecules and still retain G-CSF structural integrity. Also provided are methods for determining and preparing analog or hybrid molecules and modifications.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: July 17, 2001
    Assignee: Amgen Inc.
    Inventor: Timothy David Osslund
  • Computer apparatus for expressing a three dimensional structure of a G-CSF molecule or analogs thereof
    Patent number: 5790421
    Abstract: The present invention is directed towards a computer apparatus for expressing a three dimensional structure of a G-CSF molecule or analogs thereof.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: August 4, 1998
    Assignee: Amgen Inc.
    Inventor: Timothy David Osslund